Cultivated pet food shows how biomanufacturing can reach the market through focused products with manageable volume requirements, defined regulatory routes, and clear customer value. It turns pet nutrition into a proving ground for cell cultivation, precision fermentation, cost control, and reliable production.
That makes the pet food aisle more than an unusual entry point for animal-free protein. It gives manufacturers a place to gather production data, test supply chains, earn early revenue, and learn what buyers need before pursuing larger food markets. You can also use its progress to separate practical manufacturing advances from claims that still need stronger evidence.
What Is Cultivated Pet Food And How Is It Made?
Cultivated pet food contains animal cells grown under controlled conditions rather than meat obtained through conventional livestock production. Manufacturers begin with selected cells, establish a cell bank, multiply the cells in nutrient-rich growth media, and harvest the resulting material for use in treats, toppers, or formulated pet food.
The cells usually grow inside sealed vessels called bioreactors. Operators regulate temperature, acidity, oxygen, nutrient delivery, mixing, and contamination controls throughout production. Once enough cellular material has grown, it can be collected and combined with other ingredients through familiar pet food processes, including cooking, drying, forming, and packaging.
This method differs from plant-based pet food because the cultivated material comes from animal cells. It also differs from precision fermentation, which programs microorganisms such as yeast to produce selected animal proteins. Cell cultivation grows animal biomass, whereas precision fermentation uses microbial production to make a target ingredient.
Why Is Cultivated Pet Food An Early Market For Biomanufacturing?
Pet food gives biomanufacturers a focused route to commercial testing without requiring immediate production of large steaks, fillets, or other structured products. A treat or topper can use a smaller amount of cultivated material, which reduces the initial volume a facility must produce consistently.
Product design matters as much as production volume. A manufacturer can blend cultivated cells with approved carbohydrates, fats, fibers, vitamins, minerals, and other protein sources. This lowers the pressure to recreate every structural feature of conventional meat and lets the developer focus on nutrition, flavor, digestibility, and manufacturing stability.
Pet owners also buy products across a wide range of formats and prices. Premium treats, limited-ingredient recipes, and specialized foods can support controlled market entry before a new ingredient becomes suitable for mass-market kibble. That progression gives a company room to measure repeat purchases, production yields, batch consistency, and customer concerns without building enormous capacity at the outset.
What Did Meatly’s UK Approval And Product Sale Prove?
Meatly demonstrated that cultivated animal cells could move beyond research and enter a regulated pet food supply chain. The company received authorization from UK authorities to produce cultivated chicken for pet food, then supplied the ingredient for a limited release of dog treats created with THE PACK and sold through Pets at Home.
The release was small, so it didn’t prove that cultivated pet food was ready for broad retail distribution. It did prove that cell sourcing, growth media, production controls, ingredient handling, formulation, packaging, and retail coordination could be connected in a real commercial process. That operational record carries more weight than a laboratory tasting or prototype announcement.
Meatly’s current priority is scaling production and reducing unit costs. The company has announced funding for a pilot facility built around a 20,000-liter bioreactor and says it aims to support continuing product sales after the facility comes online. Its progress shows what comes after authorization: raising capital, commissioning equipment, validating larger batches, securing customers, and maintaining quality as output rises.
Which Biomanufacturing Models Are Emerging In Pet Food?
Three models now show how pet nutrition can support different forms of biomanufacturing. Meatly cultivates chicken cells, BioCraft Pet Nutrition develops animal cell-cultured ingredients, and Bond Pet Foods produces animal proteins through precision fermentation. Their processes aren’t interchangeable, yet each uses controlled biological production to reduce dependence on conventional animal agriculture.
BioCraft has focused on cultivated mouse ingredients for cat food, linking the choice of cells to feline nutrition and natural prey. The company has received registration in Austria that enables it to supply qualifying cell-cultured ingredients to pet food producers in the European Union. It has also announced work with pet food manufacturer Prefera Petfood on a cat food formulation containing a large share of cultivated animal cells.
Bond and Hill’s Pet Nutrition have pursued a different route. Bond uses yeast fermentation to produce animal proteins and received a Food and Drug Administration (FDA) Center for Veterinary Medicine letter of no objection for a lamb protein yeast ingredient intended for healthy adult dog food. The companies reported commercial-scale production, feeding research, and regulatory review, showing how established fermentation infrastructure can move engineered proteins toward mainstream formulation.
Why Do Regulation And Product Design Shape Market Entry?
Pet food doesn’t bypass regulation, and its route isn’t automatically easier in every country. The path differs from human food because regulators assess the ingredient under animal food rules, manufacturing requirements, labeling standards, intended use, and species-specific safety considerations.
In the United States, the FDA Center for Veterinary Medicine regulates animal food, including pet food ingredients made from cultured animal cells. A new ingredient may require a food additive pathway or evidence that qualified experts generally recognize it as safe for a defined use. State feed authorities and the Association of American Feed Control Officials (AAFCO) also influence ingredient definitions, labeling, and distribution requirements.
Cultivated human food made from certain animal species involves responsibilities shared between the FDA and the United States Department of Agriculture Food Safety and Inspection Service. Animal food remains under FDA authority at the federal level. That difference can reduce agency handoffs, but developers must still document cell lines, inputs, manufacturing controls, contaminants, nutritional performance, intended inclusion levels, and truthful labeling.
Can Cost And Bioreactor Scale Support Commercial Production?
Cost depends on much more than the size of a bioreactor. You need to examine growth media, cell productivity, batch time, contamination losses, energy use, labor, equipment depreciation, cleaning, downstream processing, ingredient concentration, and the percentage used in the finished product.
Growth media has historically been one of the largest barriers because animal cells require carefully balanced nutrients and growth signals. A pet food producer can improve the economics by reducing expensive media components, increasing cell density, shortening production cycles, and limiting material lost during harvesting. Media must also meet safety requirements and deliver repeatable performance across many batches.
Larger equipment can reduce certain costs per unit, but scale creates engineering problems of its own. Mixing, oxygen transfer, heat removal, sensor accuracy, sterility, and cell damage become harder to manage as vessel volume grows. A smaller process that delivers dependable yields can outperform a larger facility plagued by failed batches or long production interruptions.
Pet products give manufacturers several levers for managing these economics. Cultivated material can first appear in treats or blended recipes rather than serving as the entire product. Producers can then raise inclusion levels as output grows, costs fall, and feeding data supports wider use.
What Must Cultivated Pet Food Prove About Safety And Nutrition?
A regulatory milestone supports one ingredient and intended use, not every product produced through the same technology. You should assess a cultivated pet food by reviewing its formulation, nutrient profile, feeding suitability, manufacturer controls, and approval status where it is sold.
Process safety begins with the cell bank and continues through media preparation, cultivation, harvesting, storage, and final processing. Manufacturers must control microbial contamination, unwanted residues, batch variation, allergens, chemical hazards, and physical contaminants. Regulators may also review the identity of the cells, the composition of production inputs, facility sanitation, testing methods, and product labeling.
Nutrition requires the same care applied to any commercial pet food. Animal cells can supply protein, amino acids, fats, vitamins, and minerals, but a cultivated ingredient doesn’t automatically create a complete and balanced diet. Dogs and cats have different nutritional needs, and cats require careful formulation around nutrients that include taurine.
A treat has a different nutritional job from a daily diet. You can’t judge a complete food using the same criteria applied to an occasional snack. Product labels, nutritional adequacy statements, intended life stage, feeding directions, and veterinary guidance remain relevant regardless of how the protein was produced.
Is Cultivated Pet Food More Sustainable And Will Owners Accept It?
Cultivated production has the potential to reduce reliance on livestock, but environmental performance must be measured at the product and facility level. Electricity sources, media ingredients, production yields, equipment utilization, water treatment, cooling, and downstream processing all affect the result.
Comparisons also need matching boundaries. Comparing a cultivated ingredient with a premium meat cut can produce a different result from comparing it with animal byproducts already used in pet food. Credible claims need a life cycle assessment that explains what was measured, which production scale was modeled, and how ingredients and energy were sourced.
Owner acceptance will depend on practical questions rather than technology alone. Buyers want to know whether the food is nutritious, safe, affordable, appetizing, legally sold, and suitable for their pet. Terms such as “lab-grown” can create an image of an artificial finished food, so brands need plain explanations of cell sourcing, growth media, production controls, and the role of other ingredients.
Price will shape adoption too. Premium treats can absorb higher ingredient costs more easily than everyday food purchased in large bags or cases. Broader acceptance is more likely when cultivated pet food matches familiar formats, delivers consistent nutrition, and gives owners a benefit they can understand without asking them to overlook cost or performance.
What Does Cultivated Pet Food Reveal About Future Biomanufacturing?
- It validates controlled biological production.
- It tests cost reduction at smaller scale.
- It creates early commercial demand.
- It builds manufacturing and buyer trust.
The Pet Food Aisle Is Becoming A Manufacturing Test Bed
Cultivated pet food reveals that biomanufacturing can advance through focused ingredients before serving the largest food markets. Meatly has connected cell cultivation with authorization and retail sale, BioCraft is building a supplier model for cultured animal biomass, and Bond is moving fermentation-derived protein toward commercial dog food. The next test is repeatable production at a price that pet food manufacturers and buyers will accept. Safety evidence, nutritional adequacy, transparent environmental measurements, and dependable supply will determine which processes endure. If those pieces align, pet nutrition won’t remain a side project for cellular agriculture; it will become one of the industries teaching biomanufacturers how to operate at commercial scale.
References
- Meatly: Regulatory Authorization for Cultivated Chicken Pet Food
- Meatly: Commercial Cultivated Pet Food Release
- Meatly: Pilot Facility And Production Scale-Up
- BioCraft Pet Nutrition: European Ingredient Registration
- Hill’s Pet Nutrition: Bond Lamb Protein Yeast Regulatory Milestone
- Bond Pet Foods: Precision Fermentation Process
- Food And Drug Administration: Animal Food Ingredients
- Food And Drug Administration: Food Made With Cultured Animal Cells
- Food Standards Agency: Hazard Identification For Cultured Animal Cell Products
- Association Of American Feed Control Officials.
Nirdosh Jagota is the Consultant & Managing Partner, GRQ Biotech Advisors. Nirdosh Jagota has over 30 years of experience in biotech and pharmaceutical industries, leading innovation in regulatory affairs and quality management.
Dr. Nirdosh Jagota has led global teams across US, Europe, Asia Pacific, Latin America, China, India, and Japan. His expertise has been instrumental in the successful submission, approval, and lifecycle management of biologics, small molecules, and vaccines.